KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Revenue: 2012-2025

Historic Revenue for Sarepta Therapeutics (SRPT) over the last 11 years, with Jun 2025 value amounting to $611.1 million.

  • Sarepta Therapeutics' Revenue rose 68.38% to $611.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.8 billion, marking a year-over-year increase of 22.84%. This contributed to the annual value of $1.9 billion for FY2024, which is 52.97% up from last year.
  • According to the latest figures from Q2 2025, Sarepta Therapeutics' Revenue is $611.1 million, which was up 445.62% from $112.0 million recorded in Q1 2025.
  • In the past 5 years, Sarepta Therapeutics' Revenue registered a high of $658.4 million during Q4 2024, and its lowest value of $112.0 million during Q1 2025.
  • Moreover, its 3-year median value for Revenue was $379.9 million (2023), whereas its average is $386.8 million.
  • Data for Sarepta Therapeutics' Revenue shows a peak YoY increase of 68.38% (in 2025) and a maximum YoY decrease of 72.91% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Revenue stood at $201.5 million in 2021, then grew by 28.28% to $258.4 million in 2022, then skyrocketed by 53.54% to $396.8 million in 2023, then soared by 65.94% to $658.4 million in 2024, then surged by 68.38% to $611.1 million in 2025.
  • Its last three reported values are $611.1 million in Q2 2025, $112.0 million for Q1 2025, and $658.4 million during Q4 2024.